ArticleAmerican journal of translational research2020
Age and race distribution in patients in phase III oncology clinical trials.
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review.The oncologist · 2025Pooled it
- Trends in Breast and Axillary Operations in Young Patients with Operable Breast Cancer from the National Cancer Database (NCDB): De-escalation of Axillary Surgery and Increased Use of Radiation.Annals of surgical oncology · 2026Article
- Eligibility criteria and study phase limit racial/ethnic enrollment in oncology clinical trials.BMC cancer · 2026Article
- Article
- Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2026Article
- Clinical, laboratory, and medication-related factors associated with in-hospital mortality among oncology patients at a tertiary hospital in Saudi Arabia.Frontiers in pharmacology · 2026Article
- Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.Future science OA · 2025Article
- Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies.Future science OA · 2025Article
- The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review.Journal of clinical and translational science · 2025Review
- Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL.Blood advances · 2024Article
- Access to cancer clinical trials for racialised older adults: an equity-focused rapid scoping review protocol.BMJ open · 2024Article
- Article
- Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting.Cancers · 2021Article
- The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges.Blood cancer journal · 2021Review
- Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.Leukemia & lymphoma · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33042473PMC7540092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.